Effects of bisphenol compounds on the growth and epithelial mesenchymal transition of MCF-7 CV human breast cancer cells

Ji-Youn Kim, Ho-Gyu Choi, Hae-Miru Lee, Geum-A Lee, Kyung-A Hwang, Kyung-Chul Choi

PDF(713 KB)
PDF(713 KB)
Journal of Biomedical Research ›› 2017, Vol. 31 ›› Issue (4) : 358-369. DOI: 10.7555/JBR.31.20160162
Original Article
Original Article

Effects of bisphenol compounds on the growth and epithelial mesenchymal transition of MCF-7 CV human breast cancer cells

Author information +
History +

Abstract

Bisphenol-A (BPA) has been considered as an endocrine disrupting chemical (EDC) because it can exert estrogenic properties. For bisphenol-S (BPS) and bisphenol-F (BPF) that are BPA analogs and substitutes, their risk to estrogen-dependent cancer has been reported rarely compared with the numerous cases of BPA. In this study, we examined whether BPA, BPS, and BPF can lead to the proliferation, migration, and epithelial mesenchymal transition (EMT) of MCF-7 clonal variant (MCF-7 CV) breast cancer cells expressing estrogen receptors (ERs). In a cell viability assay, BPA, BPS, and BPF significantly increased proliferation of MCF-7 CV cells compared to control (DMSO) as did 17β-estradiol (E2). In Western blotting assay, BPA, BPS, and BPF enhanced the protein expression of cell cycle progression genes such as cyclin D1 and E1. In addition, MCF-7 CV cells lost cell to cell contacts and acquired fibroblast-like morphology by the treatment of BPA, BPS, or BPF for 24 hours. In cell migration assay, BPA, BPS, and BPF accelerated the migration capability of MCF-7 CV cells as did E2. In relation with the EMT process, BPA, BPS, and BPF increased the protein expression ofN-cadherin, while they decreased the protein expression of E-cadherin. When BPA, BPS, and BPF were co-treated with ICI 182,780, an ER antagonist, proliferation effects were reversed, the expression of cyclin D1 and cyclin E1 was downregulated, and the altered cell migration and expression ofN-cadherin and E-cadherin by BPA, BPS, and BPF were restored to the control level. Thus, these results imply that BPS and BPF also have the risk of breast cancer progression as much as BPA in the induction of proliferation and migration of MCF-7 CV cells by regulating the protein expression of cell cycle-related genes and EMT markersvia the ER-dependent pathway.

Keywords

human breast cancer cells / endocrine disrupting chemicals / bisphenol-A / bisphenol-S / bisphenol-F / epithelial-mesenchymal transition / migration

Cite this article

Download citation ▾
Ji-Youn Kim, Ho-Gyu Choi, Hae-Miru Lee, Geum-A Lee, Kyung-A Hwang, Kyung-Chul Choi. Effects of bisphenol compounds on the growth and epithelial mesenchymal transition of MCF-7 CV human breast cancer cells. Journal of Biomedical Research, 2017, 31(4): 358‒369 https://doi.org/10.7555/JBR.31.20160162

References

[1]
Kim CW, Go  RE, Choi KC . Treatment of BG-1 ovarian cancer cells expressing estrogen receptors with lambda-cyhalothrin and cypermethrin caused a partial estrogenicity via an estrogen receptor-dependent pathway[J]. Toxicol Res, 2015, 31(4): 331–337
Pubmed
[2]
Diamanti-Kandarakis E ,  Palioura E ,  Kandarakis SA , The impact of endocrine disruptors on endocrine targets[J]. Horm Metab Res, 2010, 42(8): 543–552
Pubmed
[3]
Choi KC, Jeung  EB. The biomarker and endocrine disruptors in mammals[J]. J Reprod Dev, 2003, 49(5): 337–345
Pubmed
[4]
Kopras E, Potluri  V, Bermudez ML , Actions of endocrine-disrupting chemicals on stem/progenitor cells during development  and  disease[J]. Endocr  Relat  Cancer, 2014, 21(2): T1–T12
Pubmed
[5]
Jung EM, Choi  KC, Yu FH , Effects of 17beta-estradiol and xenoestrogens on mouse embryonic stem cells[J]. Toxicol In Vitro, 2010, 24(6): 1538–1545
Pubmed
[6]
Chen MY, Ike  M, Fujita M . Acute toxicity, mutagenicity, and estrogenicity of bisphenol-A and other bisphenols[J]. Environ Toxicol, 2002, 17(1): 80–86
Pubmed
[7]
Vandenberg LN, Chahoud  I, Heindel JJ , Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A[J]. Cien Saude Colet, 2012, 17(2): 407–434
Pubmed
[8]
Staples CA, Dorn  PB, Klecka GM , A review of the environmental fate, effects, and exposures of bisphenol A[J]. Chemosphere, 1998, 36(10): 2149–2173
Pubmed
[9]
Lee HR, Hwang  KA, Park MA , Treatment with bisphenol A and methoxychlor results in the growth of human breast cancer cells and alteration of the expression of cell cycle-related genes, cyclin D1 and p21, via an estrogen receptor-dependent signaling pathway[J]. Int J Mol Med, 2012, 29(5): 883–890
Pubmed
[10]
Lee HS, Park  EJ, Oh JH , Bisphenol A exerts estrogenic effects by modulating CDK1/2 and p38 MAP kinase activity[J]. Biosci Biotechnol Biochem, 2014, 78(8): 1371–1375
Pubmed
[11]
Soto AM, Sonnenschein  C. Environmental causes of cancer: endocrine disruptors as carcinogens[J]. Nat Rev Endocrinol, 2010, 6(7): 363–370
Pubmed
[12]
Park MA, Choi  KC. Effects of 4-nonylphenol and bisphenol A on stimulation of cell growth via disruption of the transforming growth factor-β signaling pathway in ovarian cancer models[J]. Chem Res Toxicol, 2014, 27(1): 119–128
Pubmed
[13]
Russo J, Hasan Lareef  M, Balogh G , Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells[J]. J Steroid Biochem Mol Biol, 2003, 87(1): 1–25
Pubmed
[14]
Murray TJ, Maffini  MV, Ucci AA , Induction of mammary gland ductal hyperplasias and carcinoma in situ following fetal bisphenol A exposure[J]. Reprod Toxicol, 2007, 23(3): 383–390
Pubmed
[15]
Ho SM, Tang  WY, Belmonte de Frausto  J, Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4[J]. Cancer Res, 2006, 66(11): 5624–5632
Pubmed
[16]
Rochester JR, Bolden  AL. Bisphenol S and F: a systematic review and comparison of the hormonal activity of bisphenol a substitutes[J]. Environ Health Perspect, 2015, 123(7): 643–650
Pubmed
[17]
Liao C, Liu  F, Kannan K . Bisphenol s, a new bisphenol analogue, in paper products and currency bills and its association with bisphenol a residues[J]. Environ Sci Technol, 2012, 46(12): 6515–6522
Pubmed
[18]
Liao C, Kannan  K. A survey of alkylphenols, bisphenols, and triclosan in personal care products from China and the United States[J]. Arch Environ Contam Toxicol, 2014, 67(1): 50–59
Pubmed
[19]
Hanahan D, Weinberg  RA. The hallmarks of cancer[J]. Cell, 2000, 100(1): 57–70
Pubmed
[20]
Champeris Tsaniras S ,  Kanellakis N ,  Symeonidou IE , Licensing of DNA replication, cancer, pluripotency and differentiation: an interlinked world[J]? Semin Cell Dev Biol, 2014, 30(174–180.
[21]
Son H, Moon  A. Epithelial-mesenchymal transition and cell invasion[J]. Toxicol Res, 2010, 26(4): 245–252
Pubmed
[22]
Gupta N, Duda  DG. Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancer[J]. J Biomed Res, 2016, 30(3): 181–185
Pubmed
[23]
Thiery JP, Acloque  H, Huang RY , Epithelial-mesenchymal transitions in development and disease[J]. Cell, 2009, 139(5): 871–890
Pubmed
[24]
Chaffer CL, Weinberg  RA. A perspective on cancer cell metastasis[J]. Science, 2011, 331(6024): 1559–1564
Pubmed
[25]
Oh K, Moon  HG, Lee DS , Tissue transglutaminase-interleukin-6 axis facilitates peritoneal tumor spreading and metastasis of human ovarian cancer cells[J]. Lab Anim Res, 2015, 31(4): 188–197
Pubmed
[26]
Chunhacha P, Sriuranpong  V, Chanvorachote P . Epithelial-mesenchymal transition mediates anoikis resistance and enhances invasion in pleural effusion-derived human lung cancer cells[J]. Oncol Lett, 2013, 5(3): 1043–1047
Pubmed
[27]
Li Y, Arao  Y, Hall JM , Research Resource: STR DNA profile and gene expression comparisons of human BG-1 cells and a BG-1/MCF-7 clonal variant[J]. Molecular endocrinology (Baltimore, Md, 2014, 28(12): 2072–2081.
[28]
Sherr CJ. Cancer cell cycles[J]. Science, 1996, 274(5293): 1672–1677
Pubmed
[29]
Santen RJ, Boyd  NF, Chlebowski RT , Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model[J]. Endocr Relat Cancer, 2007, 14(2): 169–187
Pubmed
[30]
Giacalone PL, Daurés  JP, Ouafik L , Steroids and adrenomedullin growth patterns in human ovarian cancer cells: estrogenic-regulation assay[J]. Gynecol Oncol, 2003, 91(3): 651–656
Pubmed
[31]
Chung SH, Franceschi  S, Lambert PF . Estrogen and ERalpha: culprits in cervical cancer[J]? Trends Endocrinol Metab, 2010, 21(8): 504–511
Pubmed
[32]
Pelekanou V, Leclercq  G. Recent insights into the effect of natural and environmental estrogens on mammary development and carcinogenesis[J]. Int J Dev Biol, 2011, 55(7-9): 869–878
Pubmed
[33]
Conzen SD. Minireview: nuclear receptors and breast cancer[J]. Mol Endocrinol, 2008, 22(10): 2215–2228
Pubmed
[34]
Derouiche S, Warnier  M, Mariot P , Bisphenol A stimulates human prostate cancer cell migration via remodelling of calcium signalling[J]. Springerplus, 2013, 2(1): 54
Pubmed
[35]
Folkerd EJ, Dowsett  M. Influence of sex hormones on cancer progression[J]. J Clin Oncol, 2010, 28(26): 4038–4044
Pubmed
[36]
Hsieh TH, Tsai  CF, Hsu CY , n-Butyl benzyl phthalate promotes breast cancer progression by inducing expression of lymphoid enhancer factor 1[J]. PLoS One, 2012, 7(8): e42750
Pubmed
[37]
Saha Roy S, Vadlamudi  RK. Role of estrogen receptor signaling in breast cancer metastasis[J]. Int J Breast Cancer, 2012, 2012: 654698.
[38]
Yu L, Shi  J, Cheng S , Estrogen promotes prostate cancer cell migration via paracrine release of ENO1 from stromal cells[J]. Mol Endocrinol, 2012, 26(9): 1521–1530
Pubmed
[39]
Zheng S, Huang  J, Zhou K , 17β-Estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin[J]. PLoS One, 2011, 6(7): e22439
Pubmed
[40]
Keri RA, Ho  SM, Hunt PA , An evaluation of evidence for the carcinogenic activity of bisphenol A[J]. Reprod Toxicol, 2007, 24(2): 240–252
Pubmed
[41]
Mlynarcikova A, Macho  L, Fickova M . Bisphenol A alone or in combination with estradiol modulates cell cycle- and apoptosis-related proteins and genes in MCF7 cells[J]. Endocr Regul, 2013, 47(4): 189–199
Pubmed
[42]
Bates S, Bonetta  L, MacAllan D , CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1[J]. Oncogene, 1994, 9(1): 71–79
Pubmed
[43]
Meyerson M, Harlow  E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner[J]. Mol Cell Biol, 1994, 14(3): 2077–2086
Pubmed
[44]
Barnes DM, Gillett  CE. Cyclin D1 in breast cancer[J]. Breast Cancer Res Treat, 1998, 52(1–3): 1–15
Pubmed
[45]
Keyomarsi K, O’Leary  N, Molnar G , Cyclin E, a potential prognostic marker for breast cancer[J]. Cancer Res, 1994, 54(2): 380–385
Pubmed
[46]
Nielsen NH, Arnerlöv  C, Emdin SO , Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status[J]. Br J Cancer, 1996, 74(6): 874–880
Pubmed
[47]
Xiao D, He  J. Epithelial mesenchymal transition and lung cancer[J]. J Thorac Dis, 2010, 2(3): 154–159
Pubmed
[48]
Graff JR, Herman  JG, Lapidus RG , E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas[J]. Cancer Res, 1995, 55(22): 5195–5199
Pubmed
[49]
Hazan RB, Phillips  GR, Qiao RF , Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis[J]. J Cell Biol, 2000, 148(4): 779–790
Pubmed
[50]
Nakajima S, Doi  R, Toyoda E , N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma[J]. Clin Cancer Res, 2004, 10(12 Pt 1): 4125–4133
Pubmed
[51]
Kim YS, Hwang  KA, Hyun SH , Bisphenol A and nonylphenol have the potential to stimulate the migration of ovarian cancer cells by inducing epithelial-mesenchymal transition via an estrogen receptor dependent pathway[J]. Chem Res Toxicol, 2015, 28(4): 662–671
Pubmed

Acknowledgment

This work was supported by a grant from the Next-Generation BioGreen 21 Program (no. PJ011355-2015), Rural Development Administration, Republic of Korea. In addition, this work was supported by Priority Research Centers Program through NRF funded by the Ministry of Education, Science and Technology (2015R1A6A1A04020885).

RIGHTS & PERMISSIONS

2017 2017 by the Journal of Biomedical Research. All rights reserved
PDF(713 KB)

Accesses

Citations

Detail

Sections
Recommended

/